Prescribing Sunshine: How Competition & Transparency Lower Prescription Drug Costs

November 16, 2026

The Honorable Chuck Grassley

Chairman, Committee on the Judiciary

135 Hart Senate Office Building

Washington, D.C. 20510

The Honorable Dick Durbin

Ranking Member, Committee on the Judiciary

711 Hart Senate Building

Washington, D.C. 20510

Re: Prescribing Sunshine: How Competition & Transparency Lower Prescription Drug

Costs

Dear Chairman Grassley and Ranking Member Durbin:

On behalf of the Pharmaceutical Industry Labor-Management Association (PILMA) – a

partnership between America’s leading biopharmaceutical companies and the union workers

who build and maintain their world-class research and manufacturing facilities – I write to

express our strong support for today’s hearing and to offer our perspective on the most

consequential driver of prescription drug unaffordability facing American workers and their

families.

PILMA represents a unique coalition. Our members negotiate health benefits and administer

jointly trusteed Taft-Hartley health plans, which cover approximately 12.7 million union

workers and their families – the pipefitters, electricians, ironworkers, and other skilled

tradespeople who build the facilities where life-saving medicines are discovered and

manufactured. When those plans are burdened by dysfunction and a lack of basic

transparency in the prescription drug benefit system, working families bear the cost through

higher premiums, reduced benefits, and out-of-pocket expenses that undermine the

coverage they earned through collective bargaining.

The title of today’s hearing – “Prescribing Sunshine” captures precisely the remedy that is

most needed. Research shows that more than half of every dollar spent on brand medicines

flows to insurers, pharmacy benefit managers (PBMs), and other supply chain

intermediaries.i These middlemen operate with inadequate transparency, and their practices

inflate costs for working families without adding a dollar of value to patient care.

PILMA commends Congress for securing passage of bipartisan PBM reform legislation as

part of the 2026 Consolidated Appropriations Act (CCA). The CCA’s de-linking of PBM

compensation in Medicare Part D from drug list prices, establishing flat, predetermined fees

rather than percentage-based arrangements that reward more expensive drugs, will provide

meaningful relief to patients, and we are grateful for the bipartisan commitment it required.

But we believe these reforms should go further. We encourage Congress to build on this

year’s progress and consider the following policies:

• Extend de-linking beyond Medicare Part D to the commercial market. PBM

compensation should not be tied to a medicine’s list price or structured to reward

preference for higher-cost products. This reform should apply beyond Medicare Part

D and extend to the commercial market. To that end, health plans should receive

clear information about rebates, fees, claims, and payments to affiliated companies.• Ensure PBMs aren’t steering patients toward their preferred pharmacies.

Patients should be able to use the provider, pharmacy, or treatment option that best

meets their needs rather than being directed to an affiliated business because it is

more profitable for the insurer.

• Prohibit PBM conflicts of interest and self-dealing. PBMs make discretionary

decisions – about which drugs appear on a formulary, which pharmacies are included

in participating networks, and what reimbursement rates are paid – that directly

determine what health plans, and their participants, pay for prescription drugs. Yet

few meaningful checks govern how those decisions are made, leaving self-dealing

and steering practices effectively unchecked. Congress should expressly prohibit the

conflicts of interest that currently drive formulary construction toward higher-cost

drugs, steer patients to affiliated pharmacies, and produce outcomes that benefit a

corporate parent’s bottom line rather than a patient’s health.

• Enact transparency principles – like those contained in the CCA – for third-

party administrators serving self-insured and jointly-trusteed health plans.

Health plans should have full, ready access to their own cost and claims data, a clear

accounting of all fees and compensation, and complete disclosure of payments made

to affiliated companies. That transparency would help ensure that the Taft-Hartley

plans many PILMA members rely on use healthcare dollars in the best interests of

workers and their families.

The workers who build America’s life sciences facilities have earned their healthcare benefits

through hard work and collective bargaining. They deserve an insurance market that works

for them and their families.

We urge the Committee to treat PBM and insurance reform as the top policy priority it is –

both in this Congress and the next. We stand ready to serve as a constructive partner in this

endeavor.

Thank you for your leadership and for the opportunity to contribute to this important

conversation.

Respectfully submitted,

AJ Stokes

Executive Director,

Pharmaceutical Industry Labor-Management Association

i Berkeley Research Group. The Pharmaceutical Supply Chain, 2013–2023. January 2025.

https://www.thinkbrg.com/news/more-than-half-brand-medicine-spending-goes-to-supply-chain-middlemenother-stakeholders/

DOWNLOAD LETTER HERE